Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT02368886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid cream that is commonly used to treat a variety of skin conditions and may help prevent hand-foot skin reactions in patients receiving regorafenib.
Study identification
- NCT ID
- NCT02368886
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Interventions
- Clobetasol Propionate Drug
- Pharmacological Study Other
- Quality-of-Life Assessment Other
- Regorafenib Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2015 (Actual)
- Primary completion
- Sep 1, 2017 (Actual)
- Completion
- Mar 2, 2023 (Actual)
- Last update posted
- Jun 18, 2025
2015 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Illinois CancerCare-Peoria | Peoria | Illinois | 61615 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46628 | — |
| Siouxland Regional Cancer Center | Sioux City | Iowa | 51101 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Metro Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Missouri Valley Cancer Consortium | Omaha | Nebraska | 68106 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse | New York | 13057 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Toledo Clinic Cancer Centers-Toledo | Toledo | Ohio | 43623 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| Wellmont Medical Associates Oncology and Hematology-Kingsport | Kingsport | Tennessee | 37660 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin | 54301 | — |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02368886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02368886 live on ClinicalTrials.gov.